Cargando…
Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease
Cognitive impairment is common in Parkinson's disease (PD), but often not improved by dopaminergic treatment. New treatment strategies targeting other neurotransmitter deficits are therefore of growing interest. Imaging the brain at rest (‘task-free') provides the opportunity to examine th...
Autores principales: | Borchert, Robin J, Rittman, Timothy, Passamonti, Luca, Ye, Zheng, Sami, Saber, Jones, Simon P, Nombela, Cristina, Vázquez Rodríguez, Patricia, Vatansever, Deniz, Rae, Charlotte L, Hughes, Laura E, Robbins, Trevor W, Rowe, James B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856878/ https://www.ncbi.nlm.nih.gov/pubmed/26837463 http://dx.doi.org/10.1038/npp.2016.18 |
Ejemplares similares
-
Atomoxetine and citalopram alter brain network organization in Parkinson’s disease
por: Borchert, Robin J, et al.
Publicado: (2019) -
Improving Response Inhibition in Parkinson’s Disease with Atomoxetine
por: Ye, Zheng, et al.
Publicado: (2015) -
Atomoxetine restores the response inhibition network in Parkinson’s disease
por: Rae, Charlotte L., et al.
Publicado: (2016) -
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures
por: Ye, Zheng, et al.
Publicado: (2016) -
Targeting impulsivity in Parkinson’s disease using atomoxetine
por: Kehagia, Angie A., et al.
Publicado: (2014)